Madhya Pradesh Online Journal

Diabetic Macular Edema Clinical Trials | A Drug Pipeline Analysis Report 2022 | DelveInsight

 Breaking News
  • No posts were found

Diabetic Macular Edema Clinical Trials | A Drug Pipeline Analysis Report 2022 | DelveInsight

January 23
18:13 2023
Diabetic Macular Edema Clinical Trials | A Drug Pipeline Analysis Report 2022 | DelveInsight
Diabetic Macular Edema Pipeline Insights
United States, Nevada, Las Vegas, DelveInsight’s ‘Diabetic Macular Edema Pipeline Insight 2022’ report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Macular Edema therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetic Macular Edema pipeline domain.

United States, Nevada, Las Vegas, DelveInsight’s Diabetic Macular Edema Pipeline Insight 2022 report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Macular Edema therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetic Macular Edema pipeline domain.

Key Takeaways from the Diabetic Macular Edema Pipeline Report

  • Over 65+ Diabetic Macular Edema pipeline therapies are in various stages of development, and their anticipated acceptance in the Diabetic Macular Edema market would significantly increase market revenue. 
  • Leading Diabetic Macular Edema companies developing novel drug candidates to improve the Diabetic Macular Edema treatment landscape include Mylan Pharmaceuticals, Kodiak sciences, Celltrion, and others.
  • Promising Diabetic Macular Edema pipeline therapies in various stages of development include MYL-1701P, KSI-301, CT-P42, and others.

Diabetic Macular Edema Overview

Diabetic Macular Edema (DME) is an accumulation of fluid in the macula part of the retina that controls most detailed vision abilities—due to leaking blood vessels. Diabetic Macular Edema (DME) is a potential complication of DR. Diabetic retinopathy (DR) is a complication of diabetes that may be unnoticeable in its early stages, but which can lead to vision impairment and blindness. It is caused by disruption of the blood-retinal barrier due to long-term hyperglycaemia (high blood glucose), leading to retinal thickening around the fovea. DME currently affects more than 28 million people with diabetes. 

Diabetic Macular Edema Pipeline Analysis: Drug Profile

MYL-1701P: Mylan Pharmaceuticals

MYL-1701P (also referred to as M710, as part of a partnership with Momenta Pharmaceuticals) is perhaps the aflibercept biosimilar that is furthest along in the development process. It is currently the subject of a 324-patient phase III trial. Mylan is to handle development and commercialization. 

Discover more about the emerging Diabetic Macular Edema drugs @ Diabetic Macular Edema Treatment Drugs

Diabetic Macular Edema Key Companies

  • Mylan Pharmaceuticals
  • Kodiak sciences
  • Celltrion

Diabetic Macular Edema Pipeline Therapies

  • MYL-1701P
  • KSI-301
  • CT-P42

Diabetic Macular Edema Pipeline Therapeutics Assessment

  • By development stage
  • By product type
  • By route of administration
  • By molecule type
  • By MOA type 

Scope of the Diabetic Macular Edema Pipeline Report 

  • Coverage: Global 
  • Key Diabetic Macular Edema Companies: Mylan Pharmaceuticals, Kodiak sciences, Celltrion, and others
  • Key Diabetic Macular Edema Pipeline Therapies: MYL-1701P, KSI-301, CT-P42, and others

Find out more about the Diabetic Macular Edema treatment options in development @ Diabetic Macular Edema Clinical Trials

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Request for a sample report to know more about the leading companies in the Diabetic Macular Edema pipeline domain.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/